Cargando…
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat ato...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425610/ https://www.ncbi.nlm.nih.gov/pubmed/34396421 http://dx.doi.org/10.2340/00015555-3886 |
_version_ | 1784778484832272384 |
---|---|
author | ARIËNS, Lieneke F. M. BAKKER, Daphne S. SPEKHORST, Lotte S. VAN DER SCHAFT, Jorien THIJS, Judith L. HAECK, Inge FLINTERMAN, Annebeth E. KAMSTEEG, Marijke SCHUTTELAAR, Marie L. A. DE BRUIN-WELLER, Marjolein S. |
author_facet | ARIËNS, Lieneke F. M. BAKKER, Daphne S. SPEKHORST, Lotte S. VAN DER SCHAFT, Jorien THIJS, Judith L. HAECK, Inge FLINTERMAN, Annebeth E. KAMSTEEG, Marijke SCHUTTELAAR, Marie L. A. DE BRUIN-WELLER, Marjolein S. |
author_sort | ARIËNS, Lieneke F. M. |
collection | PubMed |
description | Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline (€379.8 (140.7–780.8)) to week 52 (€0.0 (0.0–211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice. |
format | Online Article Text |
id | pubmed-9425610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Society for Publication of Acta Dermato-Venereologica |
record_format | MEDLINE/PubMed |
spelling | pubmed-94256102022-10-20 Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry ARIËNS, Lieneke F. M. BAKKER, Daphne S. SPEKHORST, Lotte S. VAN DER SCHAFT, Jorien THIJS, Judith L. HAECK, Inge FLINTERMAN, Annebeth E. KAMSTEEG, Marijke SCHUTTELAAR, Marie L. A. DE BRUIN-WELLER, Marjolein S. Acta Derm Venereol Clinical Report Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline (€379.8 (140.7–780.8)) to week 52 (€0.0 (0.0–211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice. Society for Publication of Acta Dermato-Venereologica 2021-10-19 /pmc/articles/PMC9425610/ /pubmed/34396421 http://dx.doi.org/10.2340/00015555-3886 Text en © 2021 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license |
spellingShingle | Clinical Report ARIËNS, Lieneke F. M. BAKKER, Daphne S. SPEKHORST, Lotte S. VAN DER SCHAFT, Jorien THIJS, Judith L. HAECK, Inge FLINTERMAN, Annebeth E. KAMSTEEG, Marijke SCHUTTELAAR, Marie L. A. DE BRUIN-WELLER, Marjolein S. Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry |
title | Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry |
title_full | Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry |
title_fullStr | Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry |
title_full_unstemmed | Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry |
title_short | Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry |
title_sort | rapid and sustained effect of dupilumab on work productivity in patients with difficult-to-treat atopic dermatitis: results from the dutch bioday registry |
topic | Clinical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425610/ https://www.ncbi.nlm.nih.gov/pubmed/34396421 http://dx.doi.org/10.2340/00015555-3886 |
work_keys_str_mv | AT arienslienekefm rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT bakkerdaphnes rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT spekhorstlottes rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT vanderschaftjorien rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT thijsjudithl rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT haeckinge rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT flintermanannebethe rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT kamsteegmarijke rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT schuttelaarmariela rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry AT debruinwellermarjoleins rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry |